In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
Subscribe To Our Newsletter & Stay Updated
